Accelerated Approval Integrity Act of 2022
Official title: To amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for postapproval studies for drugs approved using accelerated approval, and for other purposes.
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Referred to the Subcommittee on Health.
Accelerated Approval Integrity Act of 2022
This bill establishes requirements relating to postapproval studies for drugs that receive accelerated approval for serious or life-threatening diseases or conditions, such as requiring product sponsors to agree in advance to conduct such studies and terminating product approval if certain benchmarks are not met.
- Introduced in House Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). H.R. 6963: Accelerated Approval Integrity Act of 2022. 117th Congress. Open America. https://openamerica.io/bill/117-HR-6963/
"H.R. 6963: Accelerated Approval Integrity Act of 2022." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-6963/.
H.R. 6963, 117th Cong. (2026), https://openamerica.io/bill/117-HR-6963/.
[H.R. 6963: Accelerated Approval Integrity Act of 2022](https://openamerica.io/bill/117-HR-6963/)